Saturday, October 31, 2026

VerifyMe Stock Surges 30% In 21 Sessions, Indicating Bullish Sentiment

VerifyMe Stock Surges 30% In 21 Sessions, Indicating Bullish Sentiment

(VIANEWS) - VerifyMe (NASDAQ: VRME) shares have experienced an astounding 30.97% gain over 21 sessions, rising from EUR1.13 to EUR1.48. This positive momentum continued Tuesday despite overall market movement; NASDAQ declined by 0.95% and reached EUR16,240.45. VerifyMe's closing price of EUR1.48 represents a 34.8% decrease from its 52-week high of EUR2.27, suggesting that while VerifyMe may have experienced some short-term growth in value, more work needs to be done before reaching its previous heights.

About VerifyMe

VerifyMe, Inc. is a technology solutions provider specializing in connecting brands with consumers while providing end-to-end logistics management. Operating through two segments: VerifyMe Solutions and PeriShip Global Solutions, VerifyMe offers brand protection and supply chain functions while PeriShip Global provides predictive analytics for optimizing delivery of time/temperature sensitive perishable products. Furthermore, INX International Ink Company serves as the strategic partner and is located in Lake Mary Florida for added flexibility.

Yearly Analysis

VerifyMe's stock has recently traded at EUR1.48, which is significantly below its 52-week high of EUR2.27 but higher than its 52-week low of EUR0.85. This could indicate some market fluctuations or volatility for VerifyMe. VerifyMe anticipates seeing sales growth of 30.5% this year, which is considered an impressive rate. Next year's expected growth is only 9.9% - considerably less than what was achieved this year. VerifyMe's EBITDA, a measure of its profitability, stands at -21.21 and indicates that its profit generation falls short of covering expenses; which may cause concern among investors. Based on this analysis, it is vital for investors to carefully consider VerifyMe's current stock price, sales growth and profitability before making investment decisions. Furthermore, considering other aspects of the company like their financial statements or management team can give an investor a clearer picture of its prospects.

Technical Analysis

VerifyMe stock is currently experiencing an upward trend, as evidenced by its worth remaining above both its 50-day and 200-day moving averages of EUR1.13 and EUR1.18, indicating a bullish sentiment for its short and long-term outlook. Today's reported volume was also significantly higher than average at 33900; this represents increased investor enthusiasm towards VerifyMe as an investment opportunity. However, VerifyMe's volatility has been relatively low over the last quarter, with an average intraday variation of only 2.89% indicating possible short-term price consolidation. Furthermore, its stochastic oscillator suggests it has reached overbought status and may soon experience a correction. Overall, VerifyMe's stock appears to be on an upward trajectory; however, investors should take caution and closely monitor volatility and overbought conditions of its shares.

Quarter Analysis

VerifyMe Sales Growth desfasoara: In the current quarter, VerifyMe's sales have experienced a negative 7.8% growth while forecasting an anticipated 1% expansion for next quarter. This indicates that although sales in the current quarter have decreased, management is hopeful about an upswing in future quarters. Growth Estimates QuartersThe company's current quarter growth estimates show an astoundingly negative 400% negative growth rate - an extremely unusual situation indeed! Forecasted revenues for the coming quarter are positive 47.1%. VerifyMe expects significant turnaround growth in its next quarter, which bodes well for investors. VerifyMe's year-on-year quarterly revenue growth stands at 7.5% and represents steady revenue increases since last year; currently sitting at 26.3M for twelve trailing months, VerifyMe already boasts a solid foundation from which it can build. With forecasted quarterly increases expected for each subsequent quarter, VerifyMe shows potential for future expansion.

Equity Analysis

VerifyMe currently boasts an EPS for its last twelve month period of EUR-0.29, suggesting negative earnings per share and its return on equity over this timeframe has been negative -26.16%, suggesting that it may not currently be profitable and providing returns for shareholders. Investors must exercise extreme caution when considering investing in companies with negative earnings per share or return on equity metrics. Conduct further research and analysis to ascertain any underlying causes that contribute to these negative financial metrics and whether there is any plan put in place by management to improve these performance measures. Compare VerifyMe's financial metrics against its industry peers to gain a better sense of its performance against its competition. When making investment decisions, investors should also carefully consider other aspects such as management team quality, growth prospects and current market conditions before making decisions based on financial metrics alone.

More news about VerifyMe (VRME).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com